CYAD-02

• Available for relapsed/refractory AML patients
• A Chimeric Antigen Receptor-T (CAR-T) therapy administered after CYFLU
• ENDOXAN (cyclophosphamide) and Fludara (fludarabine) are administered as a preconditioning chemotherapy
• Cyclophosphamide (300mg) and fludarabine (30mg) are administered 3 consecutive days before the CYAD-02 injection
• A consolidation cycle of 3 additional CYAD-02 infusions
• Clinical trial is recruiting - view on HealthTree's Clinical Trial Finder
• Enrollment: 27 patients

FHD-286

• “Blocks the activity of two proteins (BRG1 and BRM) that promote cancer cell growth. By blocking these proteins, FHD-286 may stop the growth of AML or MDS.
• It is taken orally
• On clinical hold and being investigated by the FDA for safety reasons related to differentiation syndrome
• Clinical trial number: ​​NCT04891757

AB8939

• A small molecule drug that induces rapid destabilization of microtubules (determines the shape of a cell) and is able to induce apoptosis (the death of a cell)
• 100 times more potent than doxorubicin (adriamycin)
• Clinical trial is recruiting - view on HealthTree's Clinical Trial Finder 
• The study will determine the daily, intravenous administration of AB8939 (0.9mg) in relapsed/refractory AML patients in Phase 1
• AB8939 plus azacitidine (75mg injection) will be used in Phase 2
• Enrollment: 78 participants

ONC 201

• A small molecule, DRD2 antagonist (a dopamine receptor), that inhibits tumor cell growth
• Is given 6-20 weeks after a stem cell transplant in the form of 125 mg capsules
• Patients will receive ONC 201 for a total of 52 weeks
• Clinical trial is recruiting - view on HealthTree's Clinical Trial Finder
• Enrollment: 20 participants

TCB-008

• “Gamma delta T cells which are sourced from healthy donors, expanded, and activated in large numbers prior to purification. Then, the cells are formulated and used for infusion into patients.”
• This Phase 2 clinical trial is recruiting - view on HealthTree's Clinical Trial Finder 
• For patients who failed to achieve CR (Complete Response) and/or are relapsed or refractory
• Before treatment of TCB-008 begins, all patients will receive fludarabine 30mg and cyclophosphamide 0.5g/m2
• Time frame is 24 months
• Enrollment: 148 participants

HealthTree's Clinical Trial Finder was designed to help you easily find AML specific trials that apply to you. Utilize the advanced filters feature to sort for trials by phase, age, genetic targets and location. If you need help finding a clinical trial or getting enrolled in one, call or email our Patient Navigation Team. They can be reached by calling (800) 930-5159 or emailing amlsupport@healthtree.org.